Investor Presentaiton
Performance: ongoing evolution to Specialty Medicines and Vaccines
Commercial excellence sharpened, with focus on newer, growing products
Sales (£bn)
Specialty Medicines and Vaccines
Progress of priority growth drivers
20
2% 20 %
70%
12
42%
62%
18
58%
58%
55%
60%
10
16
50%
46%
14
50%
12
40%
30%
Sales (£bn)
8
33%
28%
22%
6
0
20%
4
13%
4
7%
2
10%
2
0
0%
0
2017
2018
2019
2020
2021
2022
2017
2018
2019
2020
2021
2022
HIV
Other Specialty Medicines
Vaccines
% GSK sales
Shingrix
Nucala
Meningitis
Benlysta
Trelegy
Oncology
HIV 2DRs
cabotegravir
% GSK sales
Absolute values at AER; 2017-20 figures assume GSK sales to be former GSK Group (pre-demerger) less Consumer Healthcare. 2021-22 figures prepared on a continuing operations basis; all figures exclude COVID-19 solutions.
GSK
18View entire presentation